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Chemotherapy response assessment in stage IV melanoma
patients-comparison of (18)F-FDG-PET/CT, CT, brain MRI, and
tumormarker S-100B
Abstract
PURPOSE: This study aims to compare the use of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker
S-100B in chemotherapy response assessment of stage IV melanoma patients. METHODS: In 25
patients with stage IV melanoma, FDG-PET/CT and S-100B after 2-3 months (three cycles) of
chemotherapy was compared with baseline PET/CT and baseline S-100B. Retrospectively, the response
was correlated with the outcome. In patients with clinical suspicion for brain metastases, MRI or CCT
was performed. RESULTS: There was agreement between FDG-PET/CT and CT regarding response to
chemotherapy in all patients. There was a clear trend to a longer OS of PET/CT responders (n = 10)
compared with PET/CT non-responders (n = 15; p = 0.072) with remarkably better 1-year OS of 80%
compared to 40% (p = 0.048). There was a significant longer PFS of PET/CT responders compared with
PET/CT non-responders (p = 0.002). S-100B was normal at baseline in eight of 22 patients where it was
available. Chemotherapy response assessment with S-100B failed to show correlation with OS or PFS.
Eleven patients developed brain metastases during treatment, first detected by PET/CT in two and by
MRI or CCT in nine of 11 patients. Appearance of brain metastases was associated with a poor survival.
CONCLUSIONS: 18F-FDG-PET/CT and CT alone are equally suitable for chemotherapy response
assessment in melanoma patients and clearly superior to S-100B. PET/CT responders have better early
survival, but this is shortlived due to late therapy failure-often with brain recurrence. Additional brain
MRI for therapy response assessment in such high-risk patients is mandatory to detect brain metastases
missed by PET/CT.
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original research 
 
Abstract 
 
Purpose 
To compare the use of 18F-FDG-PET/CT, CT, brain MRI and tumormarker S-100B in 
chemotherapy response assessment of stage IV melanoma patients. 
Methods 
In 25 patients with stage IV melanoma FDG-PET/CT and S-100B after 2-3 months (3 
cycles) of chemotherapy was compared with baseline PET/CT and baseline S-100B. 
Retrospectively, the response was correlated with the outcome. In patients with 
clinical suspicion for brain metastases MRI or CCT was performed.  
Results 
There was agreement between FDG-PET/CT and CT regarding response to 
chemotherapy in all patients. There was a clear trend to a longer OS of PET/CT – 
responders (n=10) compared with PET/CT non-responders (n=15) (p=.072) with 
remarkably better 1-year OS of 80% compared to 40% (p=.048). There was a 
significant longer PFS of PET/CT-responders compared with PET/CT non-
responders (p=.002). S-100B was normal at baseline in 8 of 22 patients where it was 
available. Chemotherapy response assessment with S -100B failed to show 
correlation with OS or PFS. 11 patients developed brain metastases during 
treatment, first detected by PET/CT in 2 and by MRI or CCT in 9 of 11 patients. 
Appearance of brain metastases was associated with a poor survival. 
Conclusions 
18F-FDG-PET/CT and CT alone are equally suitable for chemotherapy response 
assessment in melanoma patients and clearly superior to S-100B. PET/CT 
responders have better early survival, but this is shortlived due to late therapy failure 
- often with brain recurrence. Additional brain MRI for therapy response assessment 
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in such high risk patients is mandatory to detect brain metastases missed by 
PET/CT. 
 3
Introduction 
Stage IV melanoma with distant metastases remains an incurable disease with a 
poor 5 year survival of 6% (1, 2). Melanoma metastases are characterized by 
relevant chemoresistance and the use of systemic therapy for patients with multiple 
unresectable distant metastases is still controversial (3, 4). Many patients with 
metastases are included in clinical trials in an attempt to determine any benefit from 
new treatment regimes. The currently used drugs have severe side effects and are 
expensive. Therefore methods to assess the early success or failure of 
chemotherapy are important to both the patient and the health care system. 
18F-FDG-PET/CT is increasingly used for initial staging of patients with high-risk 
melanoma. 18F-FDG-PET/CT with its unique combination of metabolic and 
morphologic information, has a high accuracy for metastases in these patients and is 
superior to PET alone, CT alone or conventional imaging methods in the M-staging 
situation (5-7). Preliminary studies showed that PET imaging may help to select the 
patients for surgery and has influence on the survival (8). 18F-FDG-PET and -PET/CT 
is increasingly used for neoadjuvant, adjuvant, curative or palliative chemotherapy 
response assessment in different malignant tumors such as lymphoma (9-11), 
oesophageal cancer (12, 13), lung cancer (14) and breast cancer (15), but 
publications regarding PET or PET/CT for therapy response assessment in 
melanoma patients are still very limited (16, 17).  
Serum S-100B is a useful tumormarker in melanoma patients, indicating the 
presence of distant metastases and reflecting the tumor burden. In addition, S-100B 
has prognostic implications (18-23). 
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The aim of this study was to compare the value of 18F-FDG-PET/CT, CT, brain MRI 
and tumormarker S-100B in chemotherapy response assessment of stage IV 
melanoma patients in correlation with the survival.  
 
Materials and Methods: 
Patients 
This retrospective study contains 25 consecutive patients (14 female, 11 male; mean 
age 62.3 years; range 31 – 82 years) which fulfilled the following criteria: Diagnosis 
of melanoma with proven distant metastases; Metastases were proven by biopsy in 
15 patients and by typical appearance on PET/CT imaging (multiple focal lesions with 
increased FDG-uptake not fitting to physiological, inflammatory lesions or other 
tumors) and/or rising S-100B tumormarker or other clinical findings in the remaining 
10 patients. 18F-FDG-PET/CT was performed at baseline (PET/CT 0) and after 2-3 
months (3 cylces) of chemotherapy (PET/CT 1). Contemporaneous S-100B 0 and S-
100B 1 measurements were available for comparison with 18F-FDG PET/CT data in 
22 cases. Overall 14 CCT`s and 18 brain MRI scans were performed if there was a 
suspicion for brain metastases. Imaging and therapy of the patients were performed 
between September 2004 and September 2007. 
We received approval from our institutional review board to undertake this 
retrospective study. 
Therapy 
All patients had stage IV melanoma with distant metastases and were included in 
clinical trials which used various chemotherapy regimes. In all patients the distant 
metastases were not detected at primary staging but during follow-up after resection 
of the primary tumor. In two patients the primary tumor was unknown. The different 
localisatino of the primary tumors, Breslow thickness and localisations of the distant 
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metastases are described in table 1. All patients started with a first-line therapy: 9 
patients were treated with temozolomide alone, 9 patients with dacarbazine alone 
and 7 patients with a combination of dacarbazine and thalidomide. In 9 patients first-
line chemotherapy was changed to second-line chemotherapy because of 
progression of the metastases. In the most cases cisplatin and vindesine were used 
for second-line treatment. In two patients additional immunotherapy was 
administered. Seven patients underwent surgery during the follow-up. The 
localisation of the resected metastases were: lung (n=3), brain (n=2), stomach and 
the inguinal region. 9 patients received additional radiotherapy of the following 
localisations: brain (n=5, one of them together with radiotherapy of a bone metastasis 
in the knee), thigh (n=3) and spine (n=1). 
determination and therapy response assessment with S-100B  
The determination of serum S-100B was performed with a commercially available 
immunoassay (ELISA) KIT (Sangtec 100 ELISA, Dia Sorin Inc, Stillwater, NM, USA) 
according to the instructions of the manufacturer. A definitely normal cut-upper limit  
was defined as 0.2 µg/l (the 95%-ile of blood donor samples). Values ≥0.3 µg/l were 
determined as indicative of definite melanoma metastases. The detection limit is 0.03 
µl/l (BO+3 SD). Intra-assay and inter-assay precision was estimated by analysis of 
variance (ANOVA). The within and total run reproducibility is within 10%. 
In all patients S-100B levels were determined before and during therapy. All together 
87 single S-100B-measurements were performed in 25 patients (mean 3.48 
measurements per patient). The percentage change of S-100B levels between S-
100B 0 and S-100B 1 was assessed and an increase or decrease of < 30% of S-
100B during therapy was determined as no response to chemotherapy, a decrease 
of ≥ 30% or a decrease from pathologically elevated S-100B value to a normal value 
(≤ 0.2µg/l) was determined as response to chemotherapy. 
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 PET/CT Imaging protocol 
All data were acquired on a combined PET/CT in-line system (Discovery LS or 
Discovery ST, GE Health Systems, Milwaukee, WI).  
Patients fasted for at least 4 hours prior to the scanning, which started approx. 60 
minutes (median 66 min.; range 54 – 73 min.) after the injection of 370 - 400 MBq of 
18F-FDG. All patients were tested for a normal glucose level before scanning. 
Patients with elevated glucose levels were rescheduled and scanned with normal 
glucose levels. No intravenous contrast agent was given. Initially, the CT scan was 
acquired starting from the level of the head using the following parameters: 40 mAs, 
140 kV, 0.5 sec/tube rotation, slice thickness 4.25 mm, scan length 867 mm, data-
acquisition time 22.5 seconds. The CT scan was acquired during breath holding in 
the normal expiratory position. In the patients with primary tumors in the lower 
extremities, the scanning of the lower legs was added. 
Immediately following the CT acquisition, a PET emission scan was acquired with an 
acquisition time of 3 minutes per cradle position with a one-slice overlap in 2D mode 
(matrix 128 x 128). The eight to nine cradle positions starting from the head to the 
knees resulted in an acquisition time of approximately 24-27 minutes. In the patients 
with primary tumors of the lower extremities, scanning of the lower legs was added. 
The CT data was used for the attenuation correction and the images were 
reconstructed using a standard iterative algorithm (OSEM). The acquired images 
were viewed with a software providing multiplanar reformatted images of PET alone, 
CT alone and fused PET/CT with linked cursors using AW workstation (GE Health 
Systems, Milwaukee, WI).PET/CT imaging was performed according to the recently 
published “procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0”(24). 
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Overall, 96 PET/CT scans were performed in these 25 patients (mean 3.8 per 
patient).  
Therapy response assessment with CT 
The images were reviewed and analysed by two radiologists experienced in 
oncologic CT imaging without knowledge of other imaging study results. The CT 
images were analysed for the presence and nature of focal metastatic lesions 
suspicious for metastases. 
For therapy response with CT the CT part of the 18F-FDG-PET/CT study was 
evaluated separately from the PET part. Response was assessed by comparing the 
CT part of PET/CT 0 with PET/CT 1 using the established RECIST criteria (25). No 
response was assigned to (a) patients with new metastases and/or (b) if there was 
stability (<30% decrease of the sum of the longest diameter of the target lesions) or 
progression in size of the known metastases. A therapy response was defined as 
complete disappearance of the metastases or at least 30% decrease of the sum of 
the longest diameter of the target lesions. 
 
PET/CT interpretation and measurement of SUV max. 
The 18F-FDG-PET/CT images were reviewed and analysed by two experienced 
nuclear-radiology physicians without knowledge of the results of other imaging 
studies. The PET images and the corresponding CT images of the PET/CT study 
were analysed for the presence and nature of focal lesions with an increased 18F-
FDG uptake. For all patients, the attenuation-corrected PET images were analysed. 
Lesions were interpreted as metastases if the uptake was higher than the uptake of 
the surrounding background tissue and thus a focal lesion was clearly depictable. 
18F-FDG uptake in physiological or benign variants as in muscles or pulmonary 
infiltration were excluded from the analysis. 
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Semiquantitative analysis of FDG-uptake in all suspicious lesions was performed by 
measuring the SUV max. (maximum standardized uptake value).  
 
Therapy response assessment with18F-FDG PET/CT 
Response was assessed by comparing the baseline PET/CT (PET/CT 0) with 
PET/CT 1 after 3 cycles of chemotherapy. Therapy response assessment with 18F-
FDG PET/CT was determined with a combination of PET and CT criteria as 
previously described (16): Briefly, no response was defined as increasing FDG-
uptake in the known metastases, if new metastases were detected or if there was no 
significant decrease of FDG-uptake in the known metastases visible. SUVmax. 
measurements were occasionally used if visual evaluation was not sufficient. 
Chemotherapy response was diagnosed if the decrease in size and FDG-uptake of 
the lesions was more than 30% or complete disappearance of pathological FDG-
uptake in the metastases occurred. The size of the lesions was measured on the CT 
part of the PET/CT. If new FDG-negative pulmonary nodules developed between the 
baseline and the restaging investigation, which were not calcified this was described 
as progressive disease due to lung metastases. 
Brain imaging with contrast enhanced CCT or MRI 
Brain MRI or contrast enhanced CCT was performed at different institutions in 
patients with symptoms suspicious for brain metastases like headache or neurologic 
deficits or to confirm 18F-FDG-PET/CT findings which were suspicious for brain 
metastases. So we do not have PET/CT and brain MRI contemporaneously in all 
patients. In all patients who received MRI of the brain at least T2- and T1- weighted 
images without contrast and T1-weighted images with intraveneous application of 
Gadolinium were performed. Metastases were diagnosed as contrast enhancing 
parenchymal lesions in T1-weighted images with additional surrounding edema (26). 
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CCT was performed according to established protocols before and after intravenous 
contrast administration (27). Brain images were evaluated by experienced 
neuroradiologists.  
 
Statistical Analysis 
Data were analysed on a patient basis using SPSS 15 for Windows (SPSS Inc.). 
Kaplan Meier curves were obtained comparing the overall survival (OS) and the 
progression-free survival (PFS) of responders and non-responders for each response 
assessment tool (PET/CT, CT or S-100B). Statistical significance was assessed with 
the log-rank test and Chi-Square tests. P<.05 was considered to indicate a significant 
difference.  
Results 
SUV max. of the most active metastases showed median values of 6.8 (mean 10.52; 
range 1.2 – 40.0) before therapy and 5.5 (10.58; 1.2 – 52.6) after 3 cycles of 
chemotherapy. Eighteen of 25 patients had died after a mean follow-up of 14 months 
(median 14, range 4-34 months) Advanced melanoma was the cause of death in all 
patients. Seven patients were alive, 4 in complete remission (No.4, 5, 12, 16) and 3 
with progressive disease (No. 7, 18, 21). Mean follow-up time in surviving patients 
was 18 months (range 14 – 28 months). Median overall survival was 18 months in 
PET/CT responders (n=10) and 11 months in PET/CT non-responders (n=15) 
(p=.072, log-rank test). 1-year survival was 80% and 40% respectively. Thus, 1-year-
survival was significantly better in responders compared with non-responder (p=.048, 
chi-square test). Median progression-free survival was 9 months in PET/CT 
responders and 3 months PET/CT non-responders (p=.002).  
In 11/25 patients S-100B values could not be used for follow-up: in 3 patients, S-
100B was not performed and in the remaining 8 patients S-100B values were not 
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suitable for response assessment because they were negative at baseline (median 
0.1µg/l, mean 0.08 µg/l; range 0.0 – 0.2 µg/l) despite the presence of proven distant 
metastases. So S-100B was suitable for therapy response assessment in 14 
patients: median values of 0.6µg/l (mean 1.7 µg/l; range 0.3 µg/l – 12.6µg/l) before 
and 0.5µg/l (1.3 µg/l; 0.1µg/l –7.3µg/l) after therapy. Nine of these 14 patients 
showed response and 5 showed no response. There was no significant difference in 
the 1-year survival of S-100B-responders (56%) and S-100B-non-responders (40%) 
(p=.77) and no significant correlation with OS (p=.825) or PFS (p=.070). There was 
agreement between S-100B, CT- and PET/CT response assessment in 11 of 14 
patients. In three patients (No.10, 18, 23) disagreement between imaging and S-
100B was observed: the tumormarker showed response and PET/CT showed no 
response (progression in two cases and stable disease in one case). However, two 
of these patients started with a relatively low S-100B value before therapy and 
decreased only moderately but more than 30% (0.6µg/l to 0.4µg/l and 0.3µg/l to 
0.2µg/l). In the third patient the decrease of S-100B was more impressive (12.6µg/l to 
3.1µg/l). Two of these three patients died after 6 and 11 months and one lives since 
14 months with a high tumor load and brain metastases.  
No patient had brain metastases at the beginning of systemic therapy. 11 patients 
developed brain metastases during the follow-up period and brain metastases were 
first detected in one of the follow-up PET/CT examinations in 2 and by MRI in 9 of 11 
patients. We observed 7 patients who died for brain metastases although they had 
only a low extracerebral tumor load. One patient had only brain metastases and 
otherwise a complete remission of the extracerebral tumor manifestations 3 months 
before he died (No. 8). Overall survival after diagnosis of brain metastases was very 
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poor with a median OS of 3 months (range 1 to 4 months). Only one patient was still 
alive at the end of the follow-up 8 months after diagnosis of a brain metastasis. 
 
Discussion 
Our data shows that 18F-FDG-PET/CT and CT imaging alone are effective tools for 
chemotherapy response assessment in stage IV melanoma patients. Imaging is 
superior to serial S-100B measurement for assessing overall survival.  
Despite other data supporting the value of serum S-100B as a clinical marker for 
monitoring therapy response of metastatic melanoma during systemic therapies a 
clear drawback of this tumormarker is the fact that it has a false negative rate in one 
third of patients with metastases (7, 28, 29). In the present study 36% patients failed 
to show elevated S-100B values despite the presence of proven distant metastases. 
This is in keeping with a previous study where 15 of 41 patients (37%) showed a 
false-negative S-100B before therapy of metastases (16). 
FDG-PET/CT is increasingly used for therapy assessment of different tumors (30). 
Current data regarding therapy assessment of melanoma patients with PET or 
PET/CT is limited to case reports showing the effect of limb perfusion therapy and 
one study comparing change of PET/CT findings to change of S-100B values in a 
mixed population of stage III and stage IV melanoma patients during different 
therapies (surgery or chemotherapy) (16, 17). To our knowledge, this is the first study 
comparing S-100B, FDG-PET/CT and CT alone for therapy response assessment by 
using outcome data. 
In many clinical trials CT remains the imaging modality of choice for therapy 
assessment in patients with stage IV melanoma. The big advantage of PET/CT is 
that this method provides the combination of metabolic and morphologic information. 
A recently published study compared FDG-PET/CT imaging for N- and M-staging of 
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250 consecutive melanoma patients with PET alone and CT alone showed the 
accuracy of PET/CT for M-staging was significantly higher than that of PET alone 
and CT alone (98% vs. 93% and 84%) (5). We share the experience that PET/CT is 
clearly superior to CT alone in the staging situation. Our data in the present study 
showed complete agreement in differentiating chemotherapy responders and non-
responders between CT alone and PET/CT. This contradicts the results in therapy 
response assessment in other tumors, especially lymphoma (31) where it has been 
shown that metabolic changes precede morphologic changes qualifying PET for 
effective therapy response assessment very early after initiation of the systemic 
therapy. Our results should be confirmed with a larger number of patients because 
they could have an important impact on costs: if CT is a prognostic parameter which 
is as strong as the more expensive and less available PET/(CT) in stage IV 
melanoma patients a significant reduction of imaging costs can be made. In support 
of the PET/CT we also want to state that we still use PET/CT for therapy response 
assessment because it provides very clear and convincing images, normally easy to 
interpret and to demonstrate in interdisciplinary meetings, thus enjoying a high 
acceptance rate by the referring dermatologists and oncologists in our hospital. 
Criteria for therapy response assessment are under debate especially since 
combined modalities like PET/CT are being more frequently used. The simplest 
method for therapy assessment is a visual analysis comparing the baseline and post-
therapy scans. Another approach is the use of semiquantitative measurements such 
as SUV max. or average SUV (32). This approach takes a little more time if multiple 
lesions are present but is highly reproducible and superior to visual analysis in 
specific tumors such as recently shown in lymphoma patients (33). More 
sophisticated and time-consuming measurements like total lesion glycolysis (TLG) 
promise to be more exactly to determine the tumor burdon because size and FDG-
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uptake of all lesions are assessed. In recently published papers the TLG approach 
failed to show superiority compared with the simpler SUV measurements (7, 32). 
With this paper we tried to establish combined therapy response assessment criteria 
which take morphologic (CT part) and metabolic (PET part) changes in account. We 
think specific PET/CT therapy response criteria should be evaluated and established 
for every specific type of tumor in the future in a way it has been initiated for therapy 
assessment in lymphoma (34). 
Clinically apparent brain metastases develop in about 18-46% of patients with stage 
IV disease and the prevalence is even much higher in autopsy series of patients 
dying for melanoma (35). One important drawback of PET/(CT) is the poor sensitivity 
of approx. 60% in detecting brain metastases due to the high physiological uptake in 
the normal brain (26). MRI is clearly the imaging gold standard in the detection of 
metastases. In our population brain metastases were first detected by PET/CT in 2 
and by MRI or CCT in 9 of 11 patients. Detecting and staging for brain metastases in 
melanoma patients is important for choosing individual therapy which can consist of 
surgery, radiotherapy or chemotherapy or combinations of these strategies (35, 36). 
Our data support the importance of identifying brain metastases because it seems to 
be an critival cause of early death and thus an important prognostic factor (37). 
These findings confirm the suspicion that current chemotherapy is not as able to treat 
intracerebral as extracerebral tumours. 
Our study has several limitations. This is a retrospective study which may lead to a 
selection bias. The number of patients is limited, a reason why the statistical 
calculations should be interpreted carefully. S-100B measurements were not 
available in all patients. Patients received different types of chemotherapy before the 
first response assessment scan was performed. In non-responders or patients with 
severe side-effects therapy was changed to second- or third-line drugs which by their 
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nature, are not as effective as first line drugs. In some patients with brain metastases 
irradiation of the brain and/or surgery was performed. In some patients - if 
downstaging was reached by systemic therapy - surgery of viable tumor rests was 
performed. We evaluated only the first PET/CT-scan during therapy because this was 
available in all patients an the most consistent measurement. We have chosen the 
timepoint after 3 cycles of chemotherapy and not an earlier timepoint for different 
reasons: PET scans for therapy response assessment are only reimbursed in 
Switzerland with an interval of 60 days or more; in our experience the response of 
melanoma lesions takes more time than in other tumors like lymphoma. While 
PET/CT and S-100B measurements were performed synchronously at fixed time 
points during treatment, CT- or MR imaging of the brain was performed only if there 
was a suspicion for brain metastases because of unclear PET/CT findings or 
neurological symptoms. Autopsy was not performed in all patients so the exact 
causes of death are not known and histopathological proof is obviously not available 
for all metastases. 
In conclusion, our results suggest that 18F-FDG-PET/CT or CT alone are equally 
accurate tools to differentiate short-term responders and non-responders and can be 
used in clinical trials for chemotherapy response assessment in stage IV melanoma 
patients. PET/CT showed no superiority to CT alone but imaging tools were clearly 
superior to tumormarker S-100B therapy response assessment. Additional brain MRI 
is mandatory because many patients die due to brain metastases despite a low 
extracerebral tumor load. 
 
 
 Table 1.  
Characteristics of 25 patients with chemotherapy response assessment with 18F-FDG-PET/CT, CT and S-100B and follow-up. 
No Breslow localisation mets at baseline first-line chemo PET/CT response CT response S-100B response survival follow-up final tumor load 
1   15.0 tigh
lung, adrenal, in-transit TMZ 
no no not available 4   
high load 
2   1.7 flank
lung, mediastinal, hilar 
ln 
TMZ 
yes yes yes    18
low load, brain mets 
3   4.9 foot
lung, soft tissue DTIC 
yes yes yes    18
high load 
4   5.5 arm
lung, ln, soft tissue, 
abdominal 
DTIC 
yes yes not suitable   17 
no tu 
5   6.5 arm
liver, lung, bone, ln, 
pleural effusion 
TMZ 
yes yes yes    19
no tu 
6   
  
U chest
pulmonal DTIC
no no not suitable 10   
low load, brain mets 
7 13.0  ear
lung, liver TMZ 
no no no    16
low load   
8  5.3 knee 
lung, liver, ln, soft 
tissue 
TMZ 
yes yes yes    12
only brain mets 
9   6.0 shoulder
liver, ln DTIC 
no no no    11
high load 
10   8.0 foot
ln mediast und iliacal DTIC 
no no yes    11
low load, brain mets 
11   7.0 arm
lung, bone, ln TMZ 
no no not suitable 4   
high load 
12   
  
1.7 chin
lung DTIC
no no not suitable   16 
no tu 
13   3.5 flank
liver, soft tissue TMZ 
no no no  9   
high load, brain 
mets 
14 U  rectal
liver, lung, soft tissue DTIC 
yes yes not suitable 15   
high load, brain 
mets 
 16
17
   
U=unknown; Breslow in mm; ln= lymph node; mets= metastases; chemo=chemotherapy; TMZ= temozolomide; DTIC= dacarbazine; 
THAL= thalidomide; survival and follow-up in months 
15 4.3 abdomen
 
liver, bone, ln 
TMZ 
yes yes yes    7
high load 
16   4.1 knee
 
lung, in-transit 
DTIC 
yes yes yes    14
no tu 
17    1.0 foot bone, ln
 
TMZ 
no no not suitable 5   high load 
18 1.8 arm lung, liver, soft tissue DTIC no no yes   14 
high load, brain 
mets 
19 U vagina pleura, stomach, ln DTIC + THAL yes yes not available 24   high load 
20 3.5 back choledochus, lung DTIC + THAL no no not suitable 16   low load, brain mets 
21 u unknown in-transit DTIC + THAL no no no   28 low load, brain mets 
22 2.1 arm lung DTIC + THAL no no not suitable 17   low load, brain mets 
23 1.4 lumbar lung, liver DTIC + THAL no no yes  6   low load, brain mets 
24 2.5 occipital lung DTIC + THAL no no no  4   high load 
25 U unknown ln, soft tissue DTIC + THAL yes yes not available 34   low load, brain mets 
 
 
Figures 
Figure 1. 
Overall survival of 18F-FDG-PET/CT (a)-, CT (b)- and S-100B (c) – responders and 
non-responders. 
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b 
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Fig. 2 
Progression-free survival of 18F-FDG-PET/CT (a)-, CT (b)- and S-100B (c) – 
responders and non-responders. 
a 
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Fig. 3,4 
46-year old female patient (No.2) with a melanoma resected at the flank 1 year 
before (Breslow 1.7mm). After detection of lung and mediastinal metastases in the 
baseline 18F-FDG-PET (2a) with an increased S-100B (0.6 µg/l) the patient received 
temodal chemotherapy. Follow-up 18F-FDG-PET/CT (2b) showed a partial response 
with decrease of the size and FDG-uptake in the metastases. Correspondingly S-
100B dropped to normal values (0.2µg/l). The next 18F-FDG-PET/CT (2c) showed a 
complete response with disappearance of the metastases and the S-100B remained 
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normal (0.2µg/l). The last 18F-FDG-PET/CT (2d) showed no extracerebral 
metastases but raised the suspicion of brain metastases, which was confirmed by an 
MRI of the brain (Fig. 3). S-100B failed to indicate new distant metastases (0.1 µg/l). 
The patient received radiotherapy of the brain but died 18 months after the beginning 
of the chemotherapy and 9 months after the detection of brain metastases. 
 
5 
Figure 5.  
40-year old female patient (No.5) with a melanoma resected at the arm 6 years ago 
(Breslow 6.5mm). Baseline 18F-FDG-PET/CT (a) showing metastases in the lung, 
liver and a right adrenal metastasis with hematoma. S-100B was clearly pathologic 
with an value of 1.7 µg/l. The patient was treated with temodal and the first follow-up 
18F-FDG-PET/CT (b) showed disappearance of the FDG-activity, a resolving 
hematoma in the adrenal region and disappearance of the metastases in the liver 
and lung. S-100B dropped to 0.2µg/l. The patient is alive with persisting complete 
remission at the 19 months follow-up. 
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 Figure 6. 
66-year-old male patient (No 23) after resection of a lumbar melanoma (Breslow 1.4). 
First 18F-FDG-PET/CT (a) shows no metastases. Second 18F-FDG-PET/CT (b) 
demonstrates lymph node metastases in the right axilla which were resected. Third 
18F-FDG-PET/CT (c) with postoperative changes in the right axilla without 
metastases. Fourth 18F-FDG-PET/CT (d) shows lung and liver metastases with a 
corresponding S-100B value of 12.6 µg/l. A systemic combination therapy with 
dacarbazine and thalidomide was started but the fifth 18F-FDG-PET/CT (e) shows 
progression of the metastases regarding size and FDG-activity. S-100B pretended a 
response with a decrease to 3.1 µg/l. Brain metastases were detected with MRI and 
radiation therapy of the brain as well as change to a second-line chemotherapy was 
performed. The patient died 3 months after the last 18F-FDG-PET/CT. 
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